Related Experiment Video

Updated: Mar 29, 2026

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

19.2K

Oseltamivir for influenza infection in children: risks and benefits

Susanna Esposito1, Nicola Principi1

  • 1a Paediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation , Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milan , Italy.

Expert Review of Respiratory Medicine
|December 1, 2015
PubMed

Insights

Oseltamivir is an influenza drug for children, but should only treat severe cases confirmed by lab tests. Influenza vaccination remains the best prevention method for children.

Area of Science:

  • Pediatric Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • Influenza commonly affects children annually.
  • Complications like pneumonia and febrile seizures occur, especially in infants and those with chronic conditions.
  • Oseltamivir is a frequently studied antiviral for pediatric influenza treatment and prevention.

Purpose of the Study:

  • To define appropriate use of oseltamivir in pediatric influenza cases.
  • To emphasize laboratory confirmation for oseltamivir treatment.
  • To highlight influenza vaccination as the primary prevention strategy.

Main Methods:

  • Review of existing literature on oseltamivir use in children.
  • Analysis of influenza complications and risk factors.
  • Assessment of current treatment and prevention guidelines.

Main Results:

  • Oseltamivir is indicated for severe influenza in children, ideally confirmed by laboratory tests.
  • Treatment decisions must weigh risks of complications against clinical presentation.
  • Influenza vaccination is the most effective preventive measure.

Conclusions:

  • Oseltamivir should be reserved for severe pediatric influenza cases.
  • Accurate diagnosis and risk assessment are crucial for appropriate oseltamivir use.
  • Prioritizing influenza vaccination is essential for pediatric public health.

Keywords:
Antiviral prophylaxisantiviral therapychildreninfluenzaneuraminidase inhibitoroseltamivir

More Related Videos

Optimization of a Quantitative Micro-neutralization Assay10:09

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

22.0K
Rapid Molecular Detection and Differentiation of Influenza Viruses A and B05:38

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B

Published on: January 30, 2017

16.3K

Related Concept Videos

Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
37
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
24
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
744
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
373
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
476
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330